DHHS treatment guidelines recommend Cimduo, Truvada, or Descovy (which contains TAF) over Epzicom as the preferred NRTI component for initial therapy (unless Epzicom is paired with Tivicay). Cerner Multum, Inc. "UK Summary of Product Characteristics." Increased AST (greater than 170 units/L) and ALT (greater than 170 units/L) have been reported in 3% and 2% of females using emtricitabine-tenofovir DF, respectively.Increased AST (greater than 5 x ULN) has been reported in 2% and 2% of patients using emtricitabine plus tenofovir alafenamide and emtricitabine plus tenofovir DF, respectively, each with elvitegravir plus cobicistat.Severe acute exacerbations of hepatitis have been reported in patients with hepatitis B after discontinuation of this drug and were associated with liver failure and liver decompensation in some emtricitabine-treated patients.Hepatic steatosis and hepatitis have also been reported during postmarketing experience with tenofovir DF.Decreased neutrophils (1000 to 1300/mm3: up to 13%; less than 750/mm3: up to 5%) and hemoglobin (8.5 to 10 mg/dL: 4%; less than 9.4 mg/dL: up to 2%) have been reported with emtricitabine-tenofovir DF.Anemia was common in pediatric patients using emtricitabine.-Very common (10% or more): Decreased neutrophils (up to 13%)-Common (1% to 10%): Sinusitis, upper respiratory tract infections, nasopharyngitis-Very common (10% or more): Rhinitis, increased coughIncreased serum amylase (greater than 175 units/L) has been reported in up to 8% of patients using emtricitabine-tenofovir DF.In clinical trials, nausea was the most common side effect reported in antiretroviral therapy-naive HIV-1-infected patients using emtricitabine plus tenofovir alafenamide with elvitegravir plus cobicistat.Increased amylase (greater than 2 x ULN) has been reported in 2% and 4% of patients using emtricitabine plus tenofovir alafenamide and emtricitabine plus tenofovir DF, respectively, each with elvitegravir plus cobicistat.-Common (1% to 10%): Diarrhea, nausea, abdominal pain (included abdominal pain, upper abdominal pain, lower abdominal pain, gastrointestinal pain, abdominal discomfort)-Common (1% to 10%): Diarrhea, nausea, increased serum amylase, abdominal pain (included abdominal pain, upper abdominal pain, lower abdominal pain, gastrointestinal pain, abdominal discomfort), vomiting-Common (1% to 10%): Diarrhea, vomiting, abdominal pain, flatulence, increased amylase-Very common (10% or more): Diarrhea, nausea, abdominal pain-Common (1% to 10%): Increased amylase (including increased pancreatic amylase), increased serum lipase, vomiting, dyspepsia-Very common (10% or more): Diarrhea, vomiting, nauseaIn clinical trials of HIV-1-uninfected individuals, decreased BMD was reported. Elevated ALT and AST were reported in 9% and 8% of therapy-experienced INSTI-experienced patients, respectively.The rates of AST and ALT abnormalities were higher patients coinfected with hepatitis B and/or C virus. It is highly effective in the prevention of HIV. In most cases, they do not last for a long period of time.T could he use of this drug may also have some serious consequences. It rarely causes side effects, and studies have shown it to be safer on markers of kidney and bone health than Truvada. It is recommended that patients use the information presented as a part of a broader decision-making process.If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.© 2020 eHealthMe.com. Hematology laboratory abnormality (grade 3 to 4) was reported in 2% of therapy-experienced INSTI-experienced patients, with Increased serum creatinine occurred due to inhibition of tubular secretion of creatinine without affecting renal glomerular function.
Cerner Multum, Inc. "UK Summary of Product Characteristics." It is important to note that side effects are observed only in a minority of Truvada users and in most cases, these side effects do not last for long.